ID   TY3H_HUMAN              Reviewed;         528 AA.
AC   P07101; B7ZL70; B7ZL73; Q0PWM2; Q0PWM3; Q15585; Q15588; Q15589;
AC   Q2M3B4;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 5.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Tyrosine 3-monooxygenase;
DE            EC=1.14.16.2;
DE   AltName: Full=Tyrosine 3-hydroxylase;
DE            Short=TH;
GN   Name=TH; Synonyms=TYH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=2887169; DOI=10.1016/0006-291X(87)90742-X;
RA   Kaneda N., Kobayashi K., Ichinose H., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Isolation of a novel cDNA clone for human tyrosine hydroxylase:
RT   alternative RNA splicing produces four kinds of mRNA from a single
RT   gene.";
RL   Biochem. Biophys. Res. Commun. 146:971-975(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=2882428; DOI=10.1038/326707a0;
RA   Grima B., Lamouroux A., Boni C., Julien J.-F., Javoy-Agid F.,
RA   Mallet J.;
RT   "A single human gene encoding multiple tyrosine hydroxylases with
RT   different predicted functional characteristics.";
RL   Nature 326:707-711(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2888085; DOI=10.1093/nar/15.16.6733;
RA   Kobayashi K., Kaneda N., Ichinose H., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Isolation of a full-length cDNA clone encoding human tyrosine
RT   hydroxylase type 3.";
RL   Nucleic Acids Res. 15:6733-6733(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX   PubMed=2902075; DOI=10.1093/oxfordjournals.jbchem.a122386;
RA   Kobayashi K., Kaneda N., Ichinose H., Kishi F., Nakazawa A.,
RA   Kurosawa Y., Fujita K., Nagatsu T.;
RT   "Structure of the human tyrosine hydroxylase gene: alternative
RT   splicing from a single gene accounts for generation of four mRNA
RT   types.";
RL   J. Biochem. 103:907-912(1988).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=17391063; DOI=10.1515/BC.2007.041;
RA   Roma J., Saus E., Cuadros M., Reventos J., Sanchez de Toledo J.,
RA   Gallego S.;
RT   "Characterisation of novel splicing variants of the tyrosine
RT   hydroxylase C-terminal domain in human neuroblastic tumours.";
RL   Biol. Chem. 388:419-426(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 4), AND VARIANT
RP   MET-112.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2892893; DOI=10.1111/j.1471-4159.1988.tb03009.x;
RA   le Bourdelles B., Boularand S., Boni C., Horellou P., Dumas S.,
RA   Grima B., Mallet J.;
RT   "Analysis of the 5' region of the human tyrosine hydroxylase gene:
RT   combinatorial patterns of exon splicing generate multiple regulated
RT   tyrosine hydroxylase isoforms.";
RL   J. Neurochem. 50:988-991(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-30.
RX   PubMed=2896667;
RA   Ginns E.I., Rehavi M., Martin B.M., Weller M., O'Malley K.L.,
RA   Lamarca M.E., McAllister C.G., Paul S.M.;
RT   "Expression of human tyrosine hydroxylase cDNA in invertebrate cells
RT   using a baculovirus vector.";
RL   J. Biol. Chem. 263:7406-7410(1988).
RN   [11]
RP   PHOSPHORYLATION AT SER-19 AND SER-71.
RX   PubMed=1680128;
RA   Le Bourdelles B., Horellou P., Le Caer J.P., Denefle P., Latta M.,
RA   Haavik J., Guibert B., Mayaux J.F., Mallet J.;
RT   "Phosphorylation of human recombinant tyrosine hydroxylase isoforms 1
RT   and 2: an additional phosphorylated residue in isoform 2, generated
RT   through alternative splicing.";
RL   J. Biol. Chem. 266:17124-17130(1991).
RN   [12]
RP   POSSIBLE INVOLVEMENT IN PARKINSON DISEASE.
RX   PubMed=20809526; DOI=10.1002/humu.21351;
RA   Bademci G., Edwards T.L., Torres A.L., Scott W.K., Zuchner S.,
RA   Martin E.R., Vance J.M., Wang L.;
RT   "A rare novel deletion of the tyrosine hydroxylase gene in Parkinson
RT   disease.";
RL   Hum. Mutat. 31:E1767-E1771(2010).
RN   [13]
RP   INVOLVEMENT IN ARSEGS, AND VARIANT ARSEGS LYS-412.
RX   PubMed=7814018; DOI=10.1007/BF00225091;
RA   Luedecke B., Dworniczak B., Bartholome K.;
RT   "A point mutation in the tyrosine hydroxylase gene associated with
RT   Segawa's syndrome.";
RL   Hum. Genet. 95:123-125(1995).
RN   [14]
RP   VARIANT MET-112.
RX   PubMed=7789962; DOI=10.1007/BF00209496;
RA   Luedecke B., Bartholome K.;
RT   "Frequent sequence variant in the human tyrosine hydroxylase gene.";
RL   Hum. Genet. 95:716-716(1995).
RN   [15]
RP   CHARACTERIZATION OF VARIANT ARSEGS LYS-412.
RX   PubMed=8528210; DOI=10.1093/hmg/4.7.1209;
RA   Knappskog P.M., Flatmark T., Mallet J., Luedecke B., Bartholome K.;
RT   "Recessively inherited L-DOPA-responsive dystonia caused by a point
RT   mutation (Q381K) in the tyrosine hydroxylase gene.";
RL   Hum. Mol. Genet. 4:1209-1212(1995).
RN   [16]
RP   CHARACTERIZATION OF VARIANT ARSEGS PRO-236.
RX   PubMed=8817341; DOI=10.1093/hmg/5.7.1023;
RA   Luedecke B., Knappskog P.M., Clayton P.T., Surtees R.A.H.,
RA   Clelland J.D., Heales S.J.R., Brand M.P., Bartholome K., Flatmark T.;
RT   "Recessively inherited L-DOPA-responsive parkinsonism in infancy
RT   caused by a point mutation (L205P) in the tyrosine hydroxylase gene.";
RL   Hum. Mol. Genet. 5:1023-1028(1996).
RN   [17]
RP   VARIANT ARSEGS PRO-236, AND VARIANT MET-112.
RX   PubMed=9613851;
RX   DOI=10.1002/(SICI)1096-8628(19980328)81:2<131::AID-AJMG2>3.3.CO;2-X;
RA   Kunugi H., Kawada Y., Hattori M., Ueki A., Otsuka M., Nanko S.;
RT   "Association study of structural mutations of the tyrosine hydroxylase
RT   gene with schizophrenia and Parkinson's disease.";
RL   Am. J. Med. Genet. 81:131-133(1998).
RN   [18]
RP   VARIANT MET-499.
RX   PubMed=9754624;
RX   DOI=10.1002/(SICI)1096-8628(19980907)81:5<388::AID-AJMG7>3.3.CO;2-F;
RA   Ishiguro H., Arinami T., Saito T., Akazawa S., Enomoto M.,
RA   Mitushio H., Fujishiro H., Tada K., Akimoto Y., Mifune H.,
RA   Shiozuka S., Hamaguchi H., Toru M., Shibuya H.;
RT   "Systematic search for variations in the tyrosine hydroxylase gene and
RT   their associations with schizophrenia, affective disorders, and
RT   alcoholism.";
RL   Am. J. Med. Genet. 81:388-396(1998).
RN   [19]
RP   VARIANT ARSEGS HIS-233.
RX   PubMed=9703425; DOI=10.1007/s004390050756;
RA   van den Heuvel L.P.W.J., Luiten B., Smeitink J.A.M.,
RA   de Rijk-van Andel J.F., Hyland K., Steenbergen-Spanjers G.C.H.,
RA   Janssen R.J.T., Wevers R.A.;
RT   "A common point mutation in the tyrosine hydroxylase gene in autosomal
RT   recessive L-DOPA-responsive dystonia in the Dutch population.";
RL   Hum. Genet. 102:644-646(1998).
RN   [20]
RP   VARIANT ARSEGS PHE-359.
RX   PubMed=10585338;
RA   Braeutigam C., Steenbergen-Spanjers G.C., Hoffmann G.F.,
RA   Dionisi-Vici C., van den Heuvel L.P., Smeitink J.A., Wevers R.A.;
RT   "Biochemical and molecular genetic characteristics of the severe form
RT   of tyrosine hydroxylase deficiency.";
RL   Clin. Chem. 45:2073-2078(1999).
RN   [21]
RP   VARIANT MET-112.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [22]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [23]
RP   VARIANTS ARSEGS PRO-276; MET-314; HIS-337 AND MET-494.
RX   PubMed=11246459; DOI=10.1046/j.1469-1809.2000.6410025.x;
RA   Swaans R.J.M., Rondot P., Renier W.O., Van Den Heuvel L.P.W.J.,
RA   Steenbergen-Spanjers G.C.H., Wevers R.A.;
RT   "Four novel mutations in the tyrosine hydroxylase gene in patients
RT   with infantile parkinsonism.";
RL   Ann. Hum. Genet. 64:25-31(2000).
RN   [24]
RP   VARIANT ARSEGS SER-309.
RX   PubMed=11196107; DOI=10.1023/A:1026760602577;
RA   De Lonlay P., Nassogne M.C., van Gennip A.H., van Cruchten A.C.,
RA   Billatte de Villemeur T., Cretz M., Stoll C., Launay J.M.,
RA   Steenberger-Spante G.C., van den Heuvel L.P., Wevers R.A.,
RA   Saudubray J.M., Abeling N.G.;
RT   "Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with
RT   unusual clinical and biochemical presentation.";
RL   J. Inherit. Metab. Dis. 23:819-825(2000).
RN   [25]
RP   VARIANTS ARSEGS VAL-376 AND GLY-498.
RX   PubMed=15505183; DOI=10.1212/01.WNL.0000142083.47927.0A;
RA   Schiller A., Wevers R.A., Steenbergen G.C., Blau N., Jung H.H.;
RT   "Long-term course of L-dopa-responsive dystonia caused by tyrosine
RT   hydroxylase deficiency.";
RL   Neurology 63:1524-1526(2004).
RN   [26]
RP   VARIANTS ARSEGS TYR-246 AND GLY-498.
RX   PubMed=15747353; DOI=10.1002/mds.20416;
RA   Diepold K., Schuetz B., Rostasy K., Wilken B., Hougaard P.,
RA   Guettler F., Romstad A., Birk Moeller L.;
RT   "Levodopa-responsive infantile parkinsonism due to a novel mutation in
RT   the tyrosine hydroxylase gene and exacerbation by viral infections.";
RL   Mov. Disord. 20:764-767(2005).
RN   [27]
RP   VARIANTS ARSEGS TRP-328 AND MET-399.
RX   PubMed=16049992; DOI=10.1002/pd.1193;
RA   Moeller L.B., Romstad A., Paulsen M., Hougaard P., Ormazabal A.,
RA   Pineda M., Blau N., Guettler F., Artuch R.;
RT   "Pre- and postnatal diagnosis of tyrosine hydroxylase deficiency.";
RL   Prenat. Diagn. 25:671-675(2005).
RN   [28]
RP   VARIANTS ARSEGS MET-387 AND LEU-492.
RX   PubMed=17696123; DOI=10.1002/ana.21199;
RA   Verbeek M.M., Steenbergen-Spanjers G.C., Willemsen M.A., Hol F.A.,
RA   Smeitink J., Seeger J., Grattan-Smith P., Ryan M.M., Hoffmann G.F.,
RA   Donati M.A., Blau N., Wevers R.A.;
RT   "Mutations in the cyclic adenosine monophosphate response element of
RT   the tyrosine hydroxylase gene.";
RL   Ann. Neurol. 62:422-426(2007).
RN   [29]
RP   VARIANTS ARSEGS ARG-414 AND GLN-510.
RX   PubMed=18058633; DOI=10.1055/s-2007-991151;
RA   Giovanniello T., Leuzzi V., Carducci C., Carducci C., Sabato M.L.,
RA   Artiola C., Santagata S., Pozzessere S., Antonozzi I.;
RT   "Tyrosine hydroxylase deficiency presenting with a biphasic clinical
RT   course.";
RL   Neuropediatrics 38:213-215(2007).
RN   [30]
RP   VARIANTS ARSEGS HIS-233 AND SER-247.
RX   PubMed=18554280; DOI=10.1111/j.1399-0004.2008.01039.x;
RA   Wu Z.Y., Lin Y., Chen W.J., Zhao G.X., Xie H., Murong S.X., Wang N.;
RT   "Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-
RT   responsive dystonia families.";
RL   Clin. Genet. 74:513-521(2008).
RN   [31]
RP   VARIANTS ARSEGS ALA-301; PRO-319; LEU-375; ARG-414 AND GLY-467.
RX   PubMed=19491146; DOI=10.1093/brain/awp084;
RA   Clot F., Grabli D., Cazeneuve C., Roze E., Castelnau P., Chabrol B.,
RA   Landrieu P., Nguyen K., Ponsot G., Abada M., Doummar D., Damier P.,
RA   Gil R., Thobois S., Ward A.J., Hutchinson M., Toutain A., Picard F.,
RA   Camuzat A., Fedirko E., San C., Bouteiller D., LeGuern E., Durr A.,
RA   Vidailhet M., Brice A.;
RT   "Exhaustive analysis of BH4 and dopamine biosynthesis genes in
RT   patients with Dopa-responsive dystonia.";
RL   Brain 132:1753-1763(2009).
RN   [32]
RP   VARIANTS ARSEGS TYR-207; GLY-227; THR-241; GLY-259 AND THR-394.
RX   PubMed=20430833; DOI=10.1093/brain/awq087;
RA   Willemsen M.A., Verbeek M.M., Kamsteeg E.J., de Rijk-van Andel J.F.,
RA   Aeby A., Blau N., Burlina A., Donati M.A., Geurtz B.,
RA   Grattan-Smith P.J., Haeussler M., Hoffmann G.F., Jung H.,
RA   de Klerk J.B., van der Knaap M.S., Kok F., Leuzzi V., de Lonlay P.,
RA   Megarbane A., Monaghan H., Renier W.O., Rondot P., Ryan M.M.,
RA   Seeger J., Smeitink J.A., Steenbergen-Spanjers G.C., Wassmer E.,
RA   Weschke B., Wijburg F.A., Wilcken B., Zafeiriou D.I., Wevers R.A.;
RT   "Tyrosine hydroxylase deficiency: a treatable disorder of brain
RT   catecholamine biosynthesis.";
RL   Brain 133:1810-1822(2010).
RN   [33]
RP   VARIANTS ARSEGS ARG-294; SER-315; VAL-385; THR-394 AND ARG-408.
RX   PubMed=20056467; DOI=10.1016/j.ymgme.2009.12.011;
RA   Mak C.M., Lam C.W., Siu T.S., Chan K.Y., Siu W.K., Yeung W.L., Hui J.,
RA   Wong V.C., Low L.C., Ko C.H., Fung C.W., Chen S.P., Yuen Y.P.,
RA   Lee H.C., Yau E., Chan B., Tong S.F., Tam S., Chan Y.W.;
RT   "Biochemical and molecular characterization of tyrosine hydroxylase
RT   deficiency in Hong Kong Chinese.";
RL   Mol. Genet. Metab. 99:431-433(2010).
RN   [34]
RP   VARIANTS ARSEGS PRO-441 AND GLY-498.
RX   PubMed=23939262; DOI=10.3233/JPD-2011-11006;
RA   Haugarvoll K., Bindoff L.A.;
RT   "A novel compound heterozygous tyrosine hydroxylase mutation (p.R441P)
RT   with complex phenotype.";
RL   J. Parkinson's Dis. 1:119-122(2011).
RN   [35]
RP   VARIANTS ARSEGS LEU-251; PHE-279 AND GLN-296, AND VARIANT MET-112.
RX   PubMed=21940685; DOI=10.1177/0883073811420717;
RA   Giovanniello T., Claps D., Carducci C., Carducci C., Blau N.,
RA   Vigevano F., Antonozzi I., Leuzzi V.;
RT   "A new tyrosine hydroxylase genotype associated with early-onset
RT   severe encephalopathy.";
RL   J. Child Neurol. 27:523-525(2012).
RN   [36]
RP   VARIANT ARSEGS ARG-428.
RX   PubMed=22815559; DOI=10.1212/WNL.0b013e318261714a;
RA   Stamelou M., Mencacci N.E., Cordivari C., Batla A., Wood N.W.,
RA   Houlden H., Hardy J., Bhatia K.P.;
RT   "Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency.";
RL   Neurology 79:435-441(2012).
RN   [37]
RP   VARIANTS ARSEGS HIS-233; SER-315 AND THR-382.
RX   PubMed=22264700; DOI=10.1016/j.pediatrneurol.2011.11.012;
RA   Chi C.S., Lee H.F., Tsai C.R.;
RT   "Tyrosine hydroxylase deficiency in Taiwanese infants.";
RL   Pediatr. Neurol. 46:77-82(2012).
RN   [38]
RP   VARIANTS CYS-19 AND ARG-428.
RX   PubMed=23762320; DOI=10.1371/journal.pone.0065215;
RA   Cai C., Shi W., Zeng Z., Zhang M., Ling C., Chen L., Cai C., Zhang B.,
RA   Li W.D.;
RT   "GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in
RT   familial and sporadic dopa-responsive dystonia patients.";
RL   PLoS ONE 8:E65215-E65215(2013).
RN   [39]
RP   CHARACTERIZATION OF VARIANTS ARSEGS TYR-207; GLY-227; HIS-233;
RP   PRO-236; THR-241; TYR-246; SER-247; GLY-259; PRO-276; ALA-301;
RP   SER-309; MET-314; PRO-319; TRP-328; HIS-337; PHE-359; LEU-375;
RP   VAL-376; MET-387; THR-394; MET-399; LYS-412; ARG-414; PRO-441;
RP   GLY-467; LEU-492; MET-494; GLY-498 AND GLN-510.
RX   PubMed=24753243; DOI=10.1002/humu.22565;
RA   Fossbakk A., Kleppe R., Knappskog P.M., Martinez A., Haavik J.;
RT   "Functional studies of tyrosine hydroxylase missense variants reveal
RT   distinct patterns of molecular defects in Dopa-responsive dystonia.";
RL   Hum. Mutat. 35:880-890(2014).
CC   -!- FUNCTION: Plays an important role in the physiology of adrenergic
CC       neurons.
CC   -!- CATALYTIC ACTIVITY: L-tyrosine + tetrahydrobiopterin + O(2) = L-
CC       dopa + 4a-hydroxytetrahydrobiopterin.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC   -!- ENZYME REGULATION: Phosphorylation leads to an increase in the
CC       catalytic activity.
CC   -!- PATHWAY: Catecholamine biosynthesis; dopamine biosynthesis;
CC       dopamine from L-tyrosine: step 1/2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=TH transcripts lacking exons 8 and 9 present concomitant
CC         splicing in exons 1b and 2.;
CC       Name=3; Synonyms=TH type 4;
CC         IsoId=P07101-1; Sequence=Displayed;
CC       Name=1; Synonyms=TH type 3;
CC         IsoId=P07101-2; Sequence=VSP_000543;
CC       Name=2; Synonyms=HTH-1, hTH-Delta1b,2, TH type 1;
CC         IsoId=P07101-3; Sequence=VSP_000544;
CC       Name=4; Synonyms=hTH-Delta2, TH type 2;
CC         IsoId=P07101-4; Sequence=VSP_000541;
CC       Name=5; Synonyms=hTH-Delta2,8,9;
CC         IsoId=P07101-5; Sequence=VSP_000541, VSP_054338;
CC         Note=Lacks catalytic activity.;
CC       Name=6; Synonyms=hTH-Delta1b,2,8,9;
CC         IsoId=P07101-6; Sequence=VSP_000544, VSP_054338;
CC         Note=Lacks catalytic activity.;
CC   -!- TISSUE SPECIFICITY: Mainly expressed in the brain and adrenal
CC       glands.
CC   -!- DISEASE: Segawa syndrome autosomal recessive (ARSEGS)
CC       [MIM:605407]: A form of DOPA-responsive dystonia presenting in
CC       infancy or early childhood. Dystonia is defined by the presence of
CC       sustained involuntary muscle contractions, often leading to
CC       abnormal postures. Some cases present with parkinsonian symptoms
CC       in infancy. Unlike all other forms of dystonia, it is an eminently
CC       treatable condition, due to a favorable response to L-DOPA.
CC       {ECO:0000269|PubMed:10585338, ECO:0000269|PubMed:11196107,
CC       ECO:0000269|PubMed:11246459, ECO:0000269|PubMed:15505183,
CC       ECO:0000269|PubMed:15747353, ECO:0000269|PubMed:16049992,
CC       ECO:0000269|PubMed:17696123, ECO:0000269|PubMed:18058633,
CC       ECO:0000269|PubMed:18554280, ECO:0000269|PubMed:19491146,
CC       ECO:0000269|PubMed:20056467, ECO:0000269|PubMed:20430833,
CC       ECO:0000269|PubMed:21940685, ECO:0000269|PubMed:22264700,
CC       ECO:0000269|PubMed:22815559, ECO:0000269|PubMed:23762320,
CC       ECO:0000269|PubMed:23939262, ECO:0000269|PubMed:24753243,
CC       ECO:0000269|PubMed:7814018, ECO:0000269|PubMed:8528210,
CC       ECO:0000269|PubMed:8817341, ECO:0000269|PubMed:9613851,
CC       ECO:0000269|PubMed:9703425}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=May play a role in the pathogenesis of Parkinson
CC       disease (PD). A genome-wide copy number variation analysis has
CC       identified a 34 kilobase deletion over the TH gene in a PD patient
CC       but not in any controls. {ECO:0000269|PubMed:20809526}.
CC   -!- SIMILARITY: Belongs to the biopterin-dependent aromatic amino acid
CC       hydroxylase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA61173.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tyrosine hydroxylase entry;
CC       URL="https://en.wikipedia.org/wiki/Tyrosine_hydroxylase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17589; AAA61179.1; -; mRNA.
DR   EMBL; X05290; CAA28908.1; -; mRNA.
DR   EMBL; Y00414; CAA68472.1; -; mRNA.
DR   EMBL; DQ677336; ABG73364.1; -; mRNA.
DR   EMBL; DQ677337; ABG73365.1; -; mRNA.
DR   EMBL; AC132217; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M24791; AAA61173.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M24787; AAA61173.1; JOINED; Genomic_DNA.
DR   EMBL; M24789; AAA61173.1; JOINED; Genomic_DNA.
DR   EMBL; CH471158; EAX02493.1; -; Genomic_DNA.
DR   EMBL; BC104967; AAI04968.1; -; mRNA.
DR   EMBL; BC143611; AAI43612.1; -; mRNA.
DR   EMBL; BC143614; AAI43615.1; -; mRNA.
DR   EMBL; M24791; AAA61170.1; -; Genomic_DNA.
DR   EMBL; M24787; AAA61170.1; JOINED; Genomic_DNA.
DR   EMBL; M20911; AAA61167.1; -; mRNA.
DR   CCDS; CCDS31338.1; -. [P07101-2]
DR   CCDS; CCDS7730.1; -. [P07101-3]
DR   CCDS; CCDS7731.1; -. [P07101-1]
DR   PIR; A30002; WHHUY4.
DR   RefSeq; NP_000351.2; NM_000360.3. [P07101-3]
DR   RefSeq; NP_954986.2; NM_199292.2. [P07101-1]
DR   RefSeq; NP_954987.2; NM_199293.2. [P07101-2]
DR   RefSeq; XP_011518637.1; XM_011520335.2. [P07101-4]
DR   UniGene; Hs.435609; -.
DR   PDB; 2XSN; X-ray; 2.68 A; A/B/C/D=193-528.
DR   PDB; 4J6S; X-ray; 3.08 A; E/F/G/H=1-74.
DR   PDBsum; 2XSN; -.
DR   PDBsum; 4J6S; -.
DR   ProteinModelPortal; P07101; -.
DR   SMR; P07101; -.
DR   BioGrid; 112912; 13.
DR   IntAct; P07101; 12.
DR   MINT; MINT-198913; -.
DR   STRING; 9606.ENSP00000370571; -.
DR   BindingDB; P07101; -.
DR   ChEMBL; CHEMBL1969; -.
DR   DrugBank; DB00120; L-Phenylalanine.
DR   DrugBank; DB00135; L-Tyrosine.
DR   DrugBank; DB03552; Meta-Tyrosine.
DR   DrugBank; DB00765; Metyrosine.
DR   DrugBank; DB00360; Sapropterin.
DR   iPTMnet; P07101; -.
DR   PhosphoSitePlus; P07101; -.
DR   BioMuta; TH; -.
DR   DMDM; 239938945; -.
DR   PaxDb; P07101; -.
DR   PeptideAtlas; P07101; -.
DR   PRIDE; P07101; -.
DR   Ensembl; ENST00000333684; ENSP00000328814; ENSG00000180176. [P07101-6]
DR   Ensembl; ENST00000352909; ENSP00000325951; ENSG00000180176. [P07101-3]
DR   Ensembl; ENST00000381175; ENSP00000370567; ENSG00000180176. [P07101-2]
DR   Ensembl; ENST00000381178; ENSP00000370571; ENSG00000180176. [P07101-1]
DR   GeneID; 7054; -.
DR   KEGG; hsa:7054; -.
DR   UCSC; uc001lvp.3; human. [P07101-1]
DR   CTD; 7054; -.
DR   DisGeNET; 7054; -.
DR   GeneCards; TH; -.
DR   GeneReviews; TH; -.
DR   H-InvDB; HIX0035928; -.
DR   HGNC; HGNC:11782; TH.
DR   HPA; CAB002522; -.
DR   HPA; CAB072340; -.
DR   HPA; HPA061003; -.
DR   MalaCards; TH; -.
DR   MIM; 191290; gene.
DR   MIM; 605407; phenotype.
DR   neXtProt; NX_P07101; -.
DR   OpenTargets; ENSG00000180176; -.
DR   Orphanet; 101150; Autosomal recessive dopa-responsive dystonia.
DR   PharmGKB; PA351; -.
DR   eggNOG; KOG3820; Eukaryota.
DR   eggNOG; COG3186; LUCA.
DR   GeneTree; ENSGT00390000010268; -.
DR   HOGENOM; HOG000233373; -.
DR   HOVERGEN; HBG006841; -.
DR   InParanoid; P07101; -.
DR   KO; K00501; -.
DR   OMA; PHLEYFV; -.
DR   OrthoDB; EOG091G05MZ; -.
DR   PhylomeDB; P07101; -.
DR   TreeFam; TF313327; -.
DR   BRENDA; 1.14.16.2; 2681.
DR   Reactome; R-HSA-209905; Catecholamine biosynthesis.
DR   SIGNOR; P07101; -.
DR   UniPathway; UPA00747; UER00733.
DR   GeneWiki; Tyrosine_hydroxylase; -.
DR   GenomeRNAi; 7054; -.
DR   PRO; PR:P07101; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000180176; -.
DR   CleanEx; HS_TH; -.
DR   ExpressionAtlas; P07101; baseline and differential.
DR   Genevisible; P07101; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0033162; C:melanosome membrane; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0043204; C:perikaryon; ISS:BHF-UCL.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0008021; C:synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0016597; F:amino acid binding; IEA:Ensembl.
DR   GO; GO:0035240; F:dopamine binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008199; F:ferric iron binding; IEA:Ensembl.
DR   GO; GO:0008198; F:ferrous iron binding; IEA:Ensembl.
DR   GO; GO:0019825; F:oxygen binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0034617; F:tetrahydrobiopterin binding; IEA:Ensembl.
DR   GO; GO:0004511; F:tyrosine 3-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0015842; P:aminergic neurotransmitter loading into synaptic vesicle; IEA:Ensembl.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0009887; P:animal organ morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042423; P:catecholamine biosynthetic process; TAS:Reactome.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071287; P:cellular response to manganese ion; IEA:Ensembl.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0042745; P:circadian sleep/wake cycle; IEA:Ensembl.
DR   GO; GO:0042416; P:dopamine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0006585; P:dopamine biosynthetic process from tyrosine; NAS:BHF-UCL.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0042418; P:epinephrine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0042462; P:eye photoreceptor cell development; ISS:BHF-UCL.
DR   GO; GO:0006631; P:fatty acid metabolic process; IEA:Ensembl.
DR   GO; GO:0016137; P:glycoside metabolic process; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; NAS:BHF-UCL.
DR   GO; GO:0033076; P:isoquinoline alkaloid metabolic process; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; ISS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0007617; P:mating behavior; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; ISS:BHF-UCL.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:0042136; P:neurotransmitter biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0042421; P:norepinephrine biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0018963; P:phthalate metabolic process; IEA:Ensembl.
DR   GO; GO:0052314; P:phytoalexin metabolic process; IEA:Ensembl.
DR   GO; GO:0043473; P:pigmentation; TAS:BHF-UCL.
DR   GO; GO:0008016; P:regulation of heart contraction; ISS:BHF-UCL.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IDA:BHF-UCL.
DR   GO; GO:0045472; P:response to ether; IEA:Ensembl.
DR   GO; GO:0009635; P:response to herbicide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0035902; P:response to immobilization stress; IEA:Ensembl.
DR   GO; GO:0035900; P:response to isolation stress; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.
DR   GO; GO:0046684; P:response to pyrethroid; IEA:Ensembl.
DR   GO; GO:0009651; P:response to salt stress; IEA:Ensembl.
DR   GO; GO:0009414; P:response to water deprivation; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0035176; P:social behavior; IEA:Ensembl.
DR   GO; GO:0006665; P:sphingolipid metabolic process; IEA:Ensembl.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; ISS:BHF-UCL.
DR   GO; GO:0042214; P:terpene metabolic process; IEA:Ensembl.
DR   GO; GO:0007601; P:visual perception; ISS:BHF-UCL.
DR   Gene3D; 1.10.800.10; -; 1.
DR   InterPro; IPR001273; ArAA_hydroxylase.
DR   InterPro; IPR018301; ArAA_hydroxylase_Fe/CU_BS.
DR   InterPro; IPR019774; Aromatic-AA_hydroxylase_C.
DR   InterPro; IPR005962; Tyr_3_mOase.
DR   InterPro; IPR019773; Tyrosine_3-monooxygenase-like.
DR   InterPro; IPR021164; Tyrosine_hydroxylase_CS.
DR   PANTHER; PTHR11473; PTHR11473; 1.
DR   Pfam; PF00351; Biopterin_H; 1.
DR   Pfam; PF12549; TOH_N; 3.
DR   PIRSF; PIRSF000336; TH; 1.
DR   PRINTS; PR00372; FYWHYDRXLASE.
DR   SUPFAM; SSF56534; SSF56534; 1.
DR   TIGRFAMs; TIGR01269; Tyr_3_monoox; 1.
DR   PROSITE; PS00367; BH4_AAA_HYDROXYL_1; 1.
DR   PROSITE; PS51410; BH4_AAA_HYDROXYL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Catecholamine biosynthesis;
KW   Complete proteome; Disease mutation; Dystonia; Iron; Metal-binding;
KW   Monooxygenase; Neurotransmitter biosynthesis; Oxidoreductase;
KW   Parkinson disease; Parkinsonism; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P17289}.
FT   CHAIN         2    528       Tyrosine 3-monooxygenase.
FT                                /FTId=PRO_0000205561.
FT   COMPBIAS     85     90       Poly-Ala.
FT   METAL       361    361       Iron. {ECO:0000250}.
FT   METAL       366    366       Iron. {ECO:0000250}.
FT   METAL       406    406       Iron. {ECO:0000250}.
FT   MOD_RES      19     19       Phosphoserine; by CaMK2.
FT                                {ECO:0000269|PubMed:1680128}.
FT   MOD_RES      62     62       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P24529}.
FT   MOD_RES      71     71       Phosphoserine; by CaMK2 and PKA.
FT                                {ECO:0000269|PubMed:1680128}.
FT   MOD_RES     502    502       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P24529}.
FT   VAR_SEQ      31     61       Missing (in isoform 2 and isoform 6).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17391063,
FT                                ECO:0000303|PubMed:2882428}.
FT                                /FTId=VSP_000544.
FT   VAR_SEQ      31     34       Missing (in isoform 1).
FT                                {ECO:0000303|PubMed:2888085}.
FT                                /FTId=VSP_000543.
FT   VAR_SEQ      35     61       Missing (in isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17391063}.
FT                                /FTId=VSP_000541.
FT   VAR_SEQ     264    357       Missing (in isoform 5 and isoform 6).
FT                                {ECO:0000303|PubMed:17391063}.
FT                                /FTId=VSP_054338.
FT   VARIANT      19     19       S -> C (found in a patient with ARSEGS;
FT                                unknown pathological significance;
FT                                dbSNP:rs766704202).
FT                                {ECO:0000269|PubMed:23762320}.
FT                                /FTId=VAR_072862.
FT   VARIANT     112    112       V -> M (common polymorphism;
FT                                dbSNP:rs6356).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:21940685,
FT                                ECO:0000269|PubMed:7789962,
FT                                ECO:0000269|PubMed:9613851}.
FT                                /FTId=VAR_014025.
FT   VARIANT     207    207       C -> Y (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:20430833,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072863.
FT   VARIANT     227    227       D -> G (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:20430833,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072864.
FT   VARIANT     233    233       R -> H (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity; shifted
FT                                substrate specificity from tyrosine to
FT                                phenylalanine and Dopa;
FT                                dbSNP:rs80338892).
FT                                {ECO:0000269|PubMed:18554280,
FT                                ECO:0000269|PubMed:22264700,
FT                                ECO:0000269|PubMed:24753243,
FT                                ECO:0000269|PubMed:9703425}.
FT                                /FTId=VAR_014026.
FT   VARIANT     236    236       L -> P (in ARSEGS; severe parkinsonian
FT                                symptoms in early infancy; strongly
FT                                reduced stability and catalytic activity;
FT                                rare mutation; dbSNP:rs121917763).
FT                                {ECO:0000269|PubMed:24753243,
FT                                ECO:0000269|PubMed:8817341,
FT                                ECO:0000269|PubMed:9613851}.
FT                                /FTId=VAR_014027.
FT   VARIANT     241    241       A -> T (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:20430833,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072865.
FT   VARIANT     246    246       H -> Y (in ARSEGS; loss of about 40% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:15747353,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072866.
FT   VARIANT     247    247       G -> S (in ARSEGS; loss of about 50% of
FT                                tyrosine hydroxylase activity; shifted
FT                                substrate specificity from tyrosine to
FT                                phenylalanine and Dopa;
FT                                dbSNP:rs762304556).
FT                                {ECO:0000269|PubMed:18554280,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072867.
FT   VARIANT     251    251       P -> L (in ARSEGS).
FT                                {ECO:0000269|PubMed:21940685}.
FT                                /FTId=VAR_071715.
FT   VARIANT     259    259       E -> G (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:20430833,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072868.
FT   VARIANT     276    276       T -> P (in ARSEGS; parkinsonian symptoms
FT                                in infancy; no effect on tyrosine
FT                                hydroxylase activity; dbSNP:rs28934581).
FT                                {ECO:0000269|PubMed:11246459,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_014028.
FT   VARIANT     279    279       C -> F (in ARSEGS).
FT                                {ECO:0000269|PubMed:21940685}.
FT                                /FTId=VAR_071716.
FT   VARIANT     294    294       G -> R (in ARSEGS; dbSNP:rs755536257).
FT                                {ECO:0000269|PubMed:20056467}.
FT                                /FTId=VAR_072869.
FT   VARIANT     296    296       R -> Q (in ARSEGS; dbSNP:rs199961079).
FT                                {ECO:0000269|PubMed:21940685}.
FT                                /FTId=VAR_071717.
FT   VARIANT     301    301       P -> A (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:19491146,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072870.
FT   VARIANT     309    309       F -> S (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:11196107,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072871.
FT   VARIANT     314    314       T -> M (in ARSEGS; parkinsonian symptoms
FT                                in infancy; loss of about 80% of tyrosine
FT                                hydroxylase activity; dbSNP:rs121917764).
FT                                {ECO:0000269|PubMed:11246459,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_014029.
FT   VARIANT     315    315       G -> S (in ARSEGS).
FT                                {ECO:0000269|PubMed:20056467,
FT                                ECO:0000269|PubMed:22264700}.
FT                                /FTId=VAR_071718.
FT   VARIANT     319    319       R -> P (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:19491146,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072872.
FT   VARIANT     328    328       R -> W (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:16049992,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072873.
FT   VARIANT     337    337       R -> H (in ARSEGS; parkinsonian symptoms
FT                                in infancy; no effect on tyrosine
FT                                hydroxylase activity; dbSNP:rs28934580).
FT                                {ECO:0000269|PubMed:11246459,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_014030.
FT   VARIANT     359    359       C -> F (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity;
FT                                dbSNP:rs121917765).
FT                                {ECO:0000269|PubMed:10585338,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072874.
FT   VARIANT     375    375       F -> L (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity; shifted
FT                                substrate specificity from tyrosine to
FT                                phenylalanine and Dopa).
FT                                {ECO:0000269|PubMed:19491146,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072875.
FT   VARIANT     376    376       A -> V (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:15505183,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072876.
FT   VARIANT     382    382       I -> T (in ARSEGS).
FT                                {ECO:0000269|PubMed:22264700}.
FT                                /FTId=VAR_071719.
FT   VARIANT     385    385       A -> V (in ARSEGS; dbSNP:rs763039181).
FT                                {ECO:0000269|PubMed:20056467}.
FT                                /FTId=VAR_072877.
FT   VARIANT     387    387       L -> M (in ARSEGS; no effect on tyrosine
FT                                hydroxylase activity).
FT                                {ECO:0000269|PubMed:17696123,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072878.
FT   VARIANT     394    394       I -> T (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:20056467,
FT                                ECO:0000269|PubMed:20430833,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072879.
FT   VARIANT     399    399       T -> M (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:16049992,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072880.
FT   VARIANT     408    408       G -> R (in ARSEGS; dbSNP:rs745551241).
FT                                {ECO:0000269|PubMed:20056467}.
FT                                /FTId=VAR_072881.
FT   VARIANT     412    412       Q -> K (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity; reduced
FT                                affinity for L-tyrosine;
FT                                dbSNP:rs121917762).
FT                                {ECO:0000269|PubMed:24753243,
FT                                ECO:0000269|PubMed:7814018,
FT                                ECO:0000269|PubMed:8528210}.
FT                                /FTId=VAR_014031.
FT   VARIANT     414    414       G -> R (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity;
FT                                dbSNP:rs370962049).
FT                                {ECO:0000269|PubMed:18058633,
FT                                ECO:0000269|PubMed:19491146,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072882.
FT   VARIANT     428    428       G -> R (in ARSEGS; phenotype with
FT                                prominent levodopa-responsive myoconus-
FT                                dystonia (M-D)).
FT                                {ECO:0000269|PubMed:22815559,
FT                                ECO:0000269|PubMed:23762320}.
FT                                /FTId=VAR_071720.
FT   VARIANT     441    441       R -> P (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity;
FT                                dbSNP:rs367874223).
FT                                {ECO:0000269|PubMed:23939262,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072883.
FT   VARIANT     467    467       S -> G (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:19491146,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072884.
FT   VARIANT     492    492       P -> L (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity;
FT                                dbSNP:rs767635052).
FT                                {ECO:0000269|PubMed:17696123,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072885.
FT   VARIANT     494    494       T -> M (in ARSEGS; parkinsonian symptoms
FT                                in infancy; no effect on tyrosine
FT                                hydroxylase activity; dbSNP:rs45471299).
FT                                {ECO:0000269|PubMed:11246459,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_014032.
FT   VARIANT     498    498       D -> G (in ARSEGS; loss of over 80% of
FT                                tyrosine hydroxylase activity;
FT                                dbSNP:rs771351747).
FT                                {ECO:0000269|PubMed:15505183,
FT                                ECO:0000269|PubMed:15747353,
FT                                ECO:0000269|PubMed:23939262,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072886.
FT   VARIANT     499    499       V -> M (in dbSNP:rs1800033).
FT                                {ECO:0000269|PubMed:9754624}.
FT                                /FTId=VAR_014033.
FT   VARIANT     510    510       L -> Q (in ARSEGS; complete loss of
FT                                tyrosine hydroxylase activity).
FT                                {ECO:0000269|PubMed:18058633,
FT                                ECO:0000269|PubMed:24753243}.
FT                                /FTId=VAR_072887.
FT   CONFLICT    373    373       R -> H (in Ref. 8; AAI43615).
FT                                {ECO:0000305}.
FT   CONFLICT    401    401       Y -> S (in Ref. 1; AAA61179, 2; CAA28908
FT                                and 3; CAA68472). {ECO:0000305}.
FT   HELIX       201    206       {ECO:0000244|PDB:2XSN}.
FT   TURN        216    218       {ECO:0000244|PDB:2XSN}.
FT   TURN        223    226       {ECO:0000244|PDB:2XSN}.
FT   HELIX       228    243       {ECO:0000244|PDB:2XSN}.
FT   HELIX       257    277       {ECO:0000244|PDB:2XSN}.
FT   HELIX       280    292       {ECO:0000244|PDB:2XSN}.
FT   HELIX       303    314       {ECO:0000244|PDB:2XSN}.
FT   STRAND      317    320       {ECO:0000244|PDB:2XSN}.
FT   HELIX       327    334       {ECO:0000244|PDB:2XSN}.
FT   TURN        335    337       {ECO:0000244|PDB:2XSN}.
FT   STRAND      338    341       {ECO:0000244|PDB:2XSN}.
FT   HELIX       359    365       {ECO:0000244|PDB:2XSN}.
FT   HELIX       367    370       {ECO:0000244|PDB:2XSN}.
FT   HELIX       373    386       {ECO:0000244|PDB:2XSN}.
FT   HELIX       391    403       {ECO:0000244|PDB:2XSN}.
FT   TURN        404    407       {ECO:0000244|PDB:2XSN}.
FT   STRAND      409    412       {ECO:0000244|PDB:2XSN}.
FT   STRAND      415    418       {ECO:0000244|PDB:2XSN}.
FT   HELIX       421    424       {ECO:0000244|PDB:2XSN}.
FT   HELIX       427    433       {ECO:0000244|PDB:2XSN}.
FT   STRAND      435    442       {ECO:0000244|PDB:2XSN}.
FT   HELIX       445    449       {ECO:0000244|PDB:2XSN}.
FT   STRAND      455    457       {ECO:0000244|PDB:2XSN}.
FT   STRAND      460    466       {ECO:0000244|PDB:2XSN}.
FT   HELIX       468    480       {ECO:0000244|PDB:2XSN}.
FT   STRAND      485    491       {ECO:0000244|PDB:2XSN}.
FT   TURN        492    495       {ECO:0000244|PDB:2XSN}.
FT   STRAND      496    500       {ECO:0000244|PDB:2XSN}.
FT   HELIX       503    526       {ECO:0000244|PDB:2XSN}.
SQ   SEQUENCE   528 AA;  58600 MW;  31D2D49955ACF070 CRC64;
     MPTPDATTPQ AKGFRRAVSE LDAKQAEAIM VRGQGAPGPS LTGSPWPGTA APAASYTPTP
     RSPRFIGRRQ SLIEDARKER EAAVAAAAAA VPSEPGDPLE AVAFEEKEGK AVLNLLFSPR
     ATKPSALSRA VKVFETFEAK IHHLETRPAQ RPRAGGPHLE YFVRLEVRRG DLAALLSGVR
     QVSEDVRSPA GPKVPWFPRK VSELDKCHHL VTKFDPDLDL DHPGFSDQVY RQRRKLIAEI
     AFQYRHGDPI PRVEYTAEEI ATWKEVYTTL KGLYATHACG EHLEAFALLE RFSGYREDNI
     PQLEDVSRFL KERTGFQLRP VAGLLSARDF LASLAFRVFQ CTQYIRHASS PMHSPEPDCC
     HELLGHVPML ADRTFAQFSQ DIGLASLGAS DEEIEKLSTL YWFTVEFGLC KQNGEVKAYG
     AGLLSSYGEL LHCLSEEPEI RAFDPEAAAV QPYQDQTYQS VYFVSESFSD AKDKLRSYAS
     RIQRPFSVKF DPYTLAIDVL DSPQAVRRSL EGVQDELDTL AHALSAIG
//
